SCYNEXIS, Inc. (SCYX) analyst actions
Rating and price-target actions on SCYX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the SCYX overview →
2 measured SCYX analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Press release | +3.01% | +4.90% | |
| SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections | Press release | +1.04% | -9.01% |
Keep exploring
More SCYX: earnings → · SEC filings → · SCYX overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| CRH MEDICAL CORP (CRHM) | 431 | 0.00% | 39% |
| Globus Medical, Inc. Class A (GMED) | 431 | +0.02% | 51% |
| LeMaitre Vascular, Inc. (LMAT) | 430 | +0.05% | 54% |
| TRULIEVE CANNABIS CORP (TCNNF) | 429 | +0.41% | 58% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.